198 related articles for article (PubMed ID: 32315156)
1. Genome Editing in a Wide Area of the Brain Using Dendrimer-Based Ternary Polyplexes of Cas9 Ribonucleoprotein.
Taharabaru T; Yokoyama R; Higashi T; Mohammed AFA; Inoue M; Maeda Y; Niidome T; Onodera R; Motoyama K
ACS Appl Mater Interfaces; 2020 May; 12(19):21386-21397. PubMed ID: 32315156
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronylglucosyl-β-cyclodextrin (G3) as a novel carrier for siRNA.
Abdelwahab AF; Ohyama A; Higashi T; Motoyama K; Khaled KA; Sarhan HA; Hussein AK; Arima H
J Drug Target; 2014 Dec; 22(10):927-34. PubMed ID: 25148608
[TBL] [Abstract][Full Text] [Related]
3. In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate.
Mohammed AFA; Higashi T; Motoyama K; Ohyama A; Onodera R; Khaled KA; Sarhan HA; Hussein AK; Arima H
AAPS J; 2019 Apr; 21(4):54. PubMed ID: 30993472
[TBL] [Abstract][Full Text] [Related]
4. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
Zhang S; Shen J; Li D; Cheng Y
Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
[TBL] [Abstract][Full Text] [Related]
5. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
Wilbie D; Walther J; Mastrobattista E
Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
[TBL] [Abstract][Full Text] [Related]
6. Potential use of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate (G2) as a siRNA carrier for the treatment of familial amyloidotic polyneuropathy.
Anno T; Higashi T; Hayashi Y; Motoyama K; Jono H; Ando Y; Arima H
J Drug Target; 2014 Dec; 22(10):883-90. PubMed ID: 25051178
[TBL] [Abstract][Full Text] [Related]
7. Potential use of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo.
Anno T; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
J Drug Target; 2012 Apr; 20(3):272-80. PubMed ID: 22201459
[TBL] [Abstract][Full Text] [Related]
8. Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment.
Kim SM; Shin SC; Kim EE; Kim SH; Park K; Oh SJ; Jang M
ACS Nano; 2018 Aug; 12(8):7750-7760. PubMed ID: 30028587
[TBL] [Abstract][Full Text] [Related]
9. Cas9 Ribonucleoprotein Complex Delivery: Methods and Applications for Neuroinflammation.
Campbell LA; Richie CT; Maggirwar NS; Harvey BK
J Neuroimmune Pharmacol; 2019 Dec; 14(4):565-577. PubMed ID: 31172397
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms.
Farboud B; Jarvis E; Roth TL; Shin J; Corn JE; Marson A; Meyer BJ; Patel NH; Hochstrasser ML
J Vis Exp; 2018 May; (135):. PubMed ID: 29889198
[TBL] [Abstract][Full Text] [Related]
11. Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient 'hit-and-run' genome editing.
Lyu P; Javidi-Parsijani P; Atala A; Lu B
Nucleic Acids Res; 2019 Sep; 47(17):e99. PubMed ID: 31299082
[TBL] [Abstract][Full Text] [Related]
12. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
13. Small extracellular vesicle-mediated CRISPR-Cas9 RNP delivery for cardiac-specific genome editing.
Mun D; Kang JY; Kim H; Yun N; Joung B
J Control Release; 2024 Jun; 370():798-810. PubMed ID: 38754633
[TBL] [Abstract][Full Text] [Related]
14. Possible enhancing mechanisms for gene transfer activity of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate.
Anno T; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
Int J Pharm; 2012 Apr; 426(1-2):239-247. PubMed ID: 22306427
[TBL] [Abstract][Full Text] [Related]
15. Versatile Redox-Responsive Polyplexes for the Delivery of Plasmid DNA, Messenger RNA, and CRISPR-Cas9 Genome-Editing Machinery.
Wang Y; Ma B; Abdeen AA; Chen G; Xie R; Saha K; Gong S
ACS Appl Mater Interfaces; 2018 Sep; 10(38):31915-31927. PubMed ID: 30222305
[TBL] [Abstract][Full Text] [Related]
16. Genome editing in potato via CRISPR-Cas9 ribonucleoprotein delivery.
Andersson M; Turesson H; Olsson N; Fält AS; Ohlsson P; Gonzalez MN; Samuelsson M; Hofvander P
Physiol Plant; 2018 Dec; 164(4):378-384. PubMed ID: 29572864
[TBL] [Abstract][Full Text] [Related]
17. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
18. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
[TBL] [Abstract][Full Text] [Related]
19. Cationic lipid nanoparticle-mediated delivery of a Cas9/crRNA ribonucleoprotein complex for transgene-free editing of the citrus plant genome.
Mahmoud LM; Dutt M
Plant Cell Rep; 2024 Jun; 43(7):171. PubMed ID: 38874819
[TBL] [Abstract][Full Text] [Related]
20. Optical Control of a CRISPR/Cas9 System for Gene Editing by Using Photolabile crRNA.
Zhang Y; Ling X; Su X; Zhang S; Wang J; Zhang P; Feng W; Zhu YY; Liu T; Tang X
Angew Chem Int Ed Engl; 2020 Nov; 59(47):20895-20899. PubMed ID: 33448579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
